{"favorite_id": 10200, "calc_type": "", "dosing": false, "full_title_en": "PLASMIC Score for TTP", "short_title_en": "PLASMIC Score for TTP", "medium_description_en": "Predicts ADAMTS13 deficiency in suspected thrombotic thrombocytopenic purpura (TTP) with high discrimination.", "short_description_en": "TTP probability.", "before_use": "", "instructions_en": "<p>Use in hospitalized adult inpatients with suspected thrombotic thrombocytopenic purpura (TTP) who might benefit from early initiation of plasma exchange while awaiting ADAMTS-13 results. Do not use in patients who have already undergone plasma exchange (i.e., intermediate and high risk groups, in whom therapeutic plasma exchange must be initiated immediately).</p>", "purpose_en": ["Diagnosis"], "disease_en": ["Anemia", "Thrombocytopenia", "Thrombotic Thrombocytopenic Purpura"], "specialty_en": ["Critical Care", "Emergency Medicine", "Hematology and Oncology", "Hospitalist Medicine", "Internal Medicine"], "chief_complaint_en": ["Fatigue", "Fever"], "system_en": ["Hematologic", "Vascular"], "search_abbreviation_en": ["Thrombotic thrombocytopenic purpura", "TTP", "plasmic", "plasmic score", "purpura", "thrombocytopenia", "hemolytic anemia", "ADAMTS13", "plasma", "mcv", "inr"], "slug": "plasmic-score-ttp", "seo": {"meta_description_en": "The PLASMIC Score for TTP predicts ADAMTS-13 deficiency in suspected TTP with high discrimination.", "keywords_en": "Thrombotic thrombocytopenic purpura, ttp, plasmic, plasmic score, purpura, thrombocytopenia, anemia, ADAMTS13"}, "content": {"how_to_use": {"use_case_en": "<p><span id=\"docs-internal-guid-4e8f91a2-7fff-a98f-46b8-3934a4f3d7e9\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\" role=\"presentation\">Hospitalized adult inpatients with suspected thrombotic thrombocytopenic purpura (TTP) who might benefit from early initiation of plasma exchange while awaiting ADAMTS-13 results.&nbsp;</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\" role=\"presentation\">Do not use in patients who have already undergone plasma exchange (i.e., intermediate and high risk groups, in whom therapeutic plasma exchange must be initiated immediately).</p>\n</li>\n</ul>", "pearls_pitfalls_en": "<p><span id=\"docs-internal-guid-1ceb495d-7fff-ddf8-d621-19bb1c9e0f15\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\" role=\"presentation\">TTP can have very nonspecific symptoms, so clinical suspicion must be high. Generally, very low platelets and hemolytic anemia are TTP until proven otherwise.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\" role=\"presentation\">Has high sensitivity to rule out TTP and may help distinguish TTP from a broad range of thrombotic microangiopathies.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\" role=\"presentation\">Not validated for pediatric patients.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\" role=\"presentation\">Samples for ADAMTS-13 level and ADAMTS-13 inhibitor must be drawn before initiation of any therapy (results may take a few days or longer, depending on the laboratory workflow).</p>\n</li>\n</ul>", "why_use_en": "<p><span id=\"docs-internal-guid-6f8c4c07-7fff-896b-dca9-b7cb8404acc7\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\" role=\"presentation\">Helps distinguish TTP from other causes of thrombotic microangiopathy.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\" role=\"presentation\">ADAMTS-13 confirmatory testing takes several days, so a clinical score can help clarify the clinical picture and aid in decisions to initiate treatment.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\" role=\"presentation\">Starting plasma exchange early in intermediate and high risk patients improves survival (mortality for untreated TTP is &gt;90%).</p>\n</li>\n</ul>"}, "next_steps": {"advice_en": "<p dir=\"ltr\">Low risk (PLASMIC Scores &le;4): consider alternative diagnoses.</p>\n<p dir=\"ltr\">Intermediate risk (PLASMIC Score 5): send ADAMTS-13 testing, keep close observation, obtain expert consultation, consider plasma exchange if no other cause identified.</p>\n<p dir=\"ltr\">High risk (PLASMIC Scores &ge;6): send for ADAMTS-13 testing, obtain expert consultation, immediate plasma exchange.</p>", "management_en": "<p><span id=\"docs-internal-guid-0aa13b8a-7fff-ea83-6f30-0815fb945486\"></p>\n<ul>\n<li dir=\"ltr\">\n<p dir=\"ltr\" role=\"presentation\">Most hospitals will require patients on plasma exchange to be transferred to a critical care unit for closer observation.&nbsp;</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\" role=\"presentation\">Therapeutic plasma exchange remains the first-line treatment.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\" role=\"presentation\">Plasma transfusion is indicated if plasma exchange cannot be performed immediately.&nbsp;</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\" role=\"presentation\">Red blood cell transfusion can be given to patients with severe bleeding.&nbsp;</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\" role=\"presentation\">Glucocorticosteroids are often given as adjunctive treatment.</p>\n</li>\n<li dir=\"ltr\">\n<p dir=\"ltr\" role=\"presentation\">Management is ideally carried out in consultation with hematology-oncology and transfusion medicine services.</p>\n</li>\n</ul>", "critical_actions_en": ""}, "about": {"formula_en": "<p dir=\"ltr\">Addition of the selected points:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"245\" /><col width=\"108\" /><col width=\"96\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>Variable</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>0 points</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>1 point</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>P</strong>latelet count &lt;30 x 10<sup>9</sup>/L</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">Hemo<strong>l</strong>ysis*</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>A</strong>ctive cancer**</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">History of solid-organ or <strong>s</strong>tem-cell transplant</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>M</strong>CV &lt;9.0 x 10<sup>-14</sup> L (&lt;90 fL)&nbsp;</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>I</strong>NR &lt;1.5</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>C</strong>reatinine &lt;2.0 mg/dL (176.8 &mu;mol/L)</p>\n</td>\n<td>\n<p dir=\"ltr\">No</p>\n</td>\n<td>\n<p dir=\"ltr\">Yes</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p><span id=\"docs-internal-guid-19a2a9ce-7fff-19b1-d408-701c23c7d0b5\">*Reticulocyte count &gt;2.5%, haptoglobin undetectable, or indirect bilirubin &gt;2.0 mg/dL (34.2 &micro;mol/L).</p>\n<p>**Treated for cancer within the past year.</p>\n<p dir=\"ltr\">From <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28259520\" target=\"_blank\">Bendapudi 2017</a>.</p>", "more_info_en": "<p dir=\"ltr\">Interpretation:</p>\n<div dir=\"ltr\">\n<table><colgroup><col width=\"127\" /><col width=\"127\" /><col width=\"195\" /></colgroup>\n<tbody>\n<tr>\n<td>\n<p dir=\"ltr\"><strong>PLASMIC Score</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Risk group</strong></p>\n</td>\n<td>\n<p dir=\"ltr\"><strong>Risk of severe ADAMTS13 deficiency*</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">0-4</p>\n</td>\n<td>\n<p dir=\"ltr\">Low</p>\n</td>\n<td>\n<p dir=\"ltr\">0%</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">5</p>\n</td>\n<td>\n<p dir=\"ltr\">Intermediate</p>\n</td>\n<td>\n<p dir=\"ltr\">6%</p>\n</td>\n</tr>\n<tr>\n<td>\n<p dir=\"ltr\">6-7</p>\n</td>\n<td>\n<p dir=\"ltr\">High</p>\n</td>\n<td>\n<p dir=\"ltr\">72%</p>\n</td>\n</tr>\n</tbody>\n</table>\n</div>\n<p dir=\"ltr\">*Severe deficiency was defined as ADAMTS13 activity level &lt;15%.</p>\n<p><span id=\"docs-internal-guid-c07889b3-7fff-ae8c-2ec9-e099682cbf8c\">From <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/29064619\" target=\"_blank\">Li 2018</a>.</p>", "evidence_based_medicine_en": "<p dir=\"ltr\">The PLASMIC Score was derived by <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28259520\" target=\"_blank\">Bendapudi et al</a> and externally validated in a <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28259520\" target=\"_blank\">study</a> with an independent cohort of 112 consecutive hospitalized patients with suspected thrombotic microangiopathy and appropriate ADAMTS-13 testing (including 21 patients with TTP diagnosis). The PLASMIC model predicted severe ADAMTS-13 deficiency with a c statistic of 0.94 (0.88-0.98). When dichotomized at high (scores 6-7) vs. low-intermediate risk (scores 0-5), the model predicted severe ADAMTS-13 deficiency with positive predictive value 72%, negative predictive value 98%, sensitivity 90% and specificity 92%.&nbsp;</p>\n<p dir=\"ltr\">In the low-intermediate risk group (scores 0-5), there was no significant improvement in overall survival associated with plasma exchange. The PLASMIC Score had excellent applicability, discrimination and calibration for predicting severe ADAMTS-13 deficiency. The clinical algorithm allowed identification of a subgroup of patients who lacked a significant response to empiric treatment.</p>", "references_list": {"Original/Primary Reference": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/28259520", "text": "Bendapudi PK, Hurwitz S, Fry A, et al. Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study. Lancet Haematol. 2017;4(4):e157-e164."}], "Other References": [], "Validation": [{"href": "https://www.ncbi.nlm.nih.gov/pubmed/29064619", "text": "Li A, Khalighi PR, Wu Q, Garcia DA. External validation of the PLASMIC score: a clinical prediction tool for thrombotic thrombocytopenic purpura diagnosis and treatment. J Thromb Haemost. 2018;16(1):164-169."}], "Clinical Practice Guidelines": [], "Manufacturer Website": [], "Outcomes": []}}, "contributor": {"expert_name": [{"description": "", "firstName": "Alex", "img": "", "lastName": "Lazo", "name": "Alex Lazo, MD", "target": "", "signedCOI": false, "hasDisclosure": []}]}, "creator": [{"name": "Dr. Pavan K. Bendapudi", "qa_en": "<p dir=\"ltr\"><strong>Why did you develop the PLASMIC Score for TTP? Was there a particular clinical experience or patient encounter that inspired you to create this tool for clinicians?</strong></p>\n<p dir=\"ltr\">Within hematology, TTP represents a \"sweet spot\" for the development of a bedside diagnostic score: it is a lethal disease requiring immediate initiation of therapy but for which the gold standard diagnostic test takes 3-5 days to result. Given this situation, Robert Makar and I decided to leverage our institution's electronic medical record system to put together a curated cohort of TTP patients and try to identify common characteristics that could be used in a diagnostic score.</p>\n<p dir=\"ltr\"><strong>What pearls, pitfalls and/or tips do you have for users of the PLASMIC Score for TTP? Do you know of cases when it has been applied, interpreted, or used inappropriately?</strong></p>\n<p dir=\"ltr\">The biggest mistake that clinicians make is trying to apply the score to the wrong population. The PLASMIC Score is intended for use only in patients with thrombocytopenia (platelets &lt;150) and evidence of MAHA (schistocytes) on peripheral smear.</p>\n<p dir=\"ltr\">Other tips:&nbsp;</p>\n<p dir=\"ltr\">1. Use the earliest lab value available for each parameter. Do not use any value drawn after &ge;72 hrs of hospitalization.</p>\n<p dir=\"ltr\">2. Combined hemolysis parameter: reticulocyte count &gt;2.5 OR indirect bilirubin &gt;2.0 OR haptoglobin undetectable. If any of these are positive, assign one point.</p>\n<p dir=\"ltr\">3. The PLASMIC Score is intended to support, not replace, clinical judgment.&nbsp;</p>\n<p dir=\"ltr\"><strong>What recommendations do you have for doctors once they have applied the PLASMIC Score for TTP? Are there any adjustments or updates you would make to the score based on new data or practice changes?</strong></p>\n<p dir=\"ltr\">A patient's PLASMIC Score can be used to risk stratify that individual for further workup and treatment. We recommend a cutoff of 5, i.e. score &lt;5 generally does not require further workup, score &ge;5 usually requires ADAMTS13 to be sent along with expert consultation. For more information, please see <a href=\"https://www.ncbi.nlm.nih.gov/pubmed/28597458\" target=\"_blank\">Bendapudi et al 2017</a>.</p>\n<p dir=\"ltr\"><strong>Any other research in the pipeline that you&rsquo;re particularly excited about?</strong></p>\n<p><span id=\"docs-internal-guid-1e3169e3-7fff-2ad4-7d27-aa18403ec27a\"></p>\n<p dir=\"ltr\">We continue to leverage our dataset to answer important clinical questions in the field of TTP and allied disorders, including other forms of thrombotic microangiopathy. We are also initiating a translational research program in which we are studying specimens from patients with TTP to better understand what predisposes people to TTP and how the disease may be prevented.</p>", "approved": false, "creator_info": {"about_en": "<p>Pavan K. Bendapudi, MD, is an assistant professor of medicine at Harvard Medical School. Together with Dr. Robert Makar, he is co-principal investigator of the Harvard Thrombotic Microangiopathies Research Collaborative, an interdisciplinary, multi-institutional consortium that studies TTP and allied disorders. Dr. Bendapudi\u2019s primary research is focused on humoral coagulation factors and the mechanisms underlying hemostatic and thrombotic disease.</p>", "photo_en": "https://cdn-web-img.mdcalc.com/people/dr-pavan-k-bendapudi.jpeg", "pubmedLink": "https://www.ncbi.nlm.nih.gov/pubmed/?term=Bendapudi+PK%5BAuthor%5D"}}], "reviewer": {"expert_name": [{"description": "", "firstName": "Fatima", "img": "", "lastName": "Aldarweesh", "name": "Fatima Aldarweesh, MD", "target": "", "signedCOI": true, "hasDisclosure": []}]}, "related_resources": {"mdcalc_rating": [], "guidelines": [], "teaching": [], "videos": [], "interests": [], "partner_contact": [], "sdm_tool": []}}, "input_schema": [{"type": "toggle", "label_en": "Platelet count <30 x 10<sup>9</sup>/L", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "platelet"}, {"type": "toggle", "label_en": "Hemolysis", "default": 0, "conditionality": "", "show_points": true, "tips_en": "Reticulocyte count >2.5%, haptoglobin undetectable, or indirect bilirubin >2.0 mg/dL (34.2 \u00b5mol/L)", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "reticulocyte"}, {"type": "toggle", "label_en": "Active cancer", "default": null, "conditionality": "", "show_points": true, "tips_en": "Treated for cancer within the past year", "optional": false, "options": [{"label": "No", "value": 1}, {"label": "Yes", "value": 0}], "name": "cancer"}, {"type": "toggle", "label_en": "History of solid-organ or stem-cell transplant", "default": null, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 1}, {"label": "Yes", "value": 0}], "name": "history"}, {"type": "toggle", "label_en": "<abbr title = \"Mean corpuscular volume\">MCV</abbr> <9.0 x 10<sup>-14</sup> L (<90 fL)", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "mcv"}, {"type": "toggle", "label_en": "<abbr title = \"International normalized ratio\">INR</abbr>  <1.5", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "inr"}, {"type": "toggle", "label_en": "Creatinine <2.0 mg/dL (176.8 \u03bcmol/L)", "default": 0, "conditionality": "", "show_points": true, "tips_en": "", "optional": false, "options": [{"label": "No", "value": 0}, {"label": "Yes", "value": 1}], "name": "cr"}], "md5": "", "cmeReleaseDate": null, "cmeEndDate": null, "cmeLastReviewed": null, "cmeVersion": "10200.1", "related_calcs": [{"calcId": 10125, "short_title_en": "Villalta Score", "slug": "villalta-score-post-thrombotic-syndrome-pts"}, {"calcId": 4050, "short_title_en": "DRIP Score", "slug": "drug-resistance-pneumonia-drip-score"}, {"calcId": 1667, "short_title_en": "Absolute Reticulocyte Count", "slug": "absolute-reticulocyte-count-reticulocyte-index"}]}